Last €124.22 EUR
Change Today -2.19 / -1.73%
Volume 38.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:19 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1040 Spring Street

Silver Spring, MD 20910

United States

Phone: 301-608-9292

Fax: 301-608-9291

ccredo) and CVS Caremark (Caremark) to distribute both Remodulin and Tyvaso. The company sells Adcirca to pharmaceutical wholesalers. The company sells subcutaneous and intravenous Remodulin outside the United States to various distributors, each of which has exclusive distribution rights in one or more countries within Europe, Israel and the Middle East, Asia and South and Central America. The company also distributes Remodulin in Canada through a specialty pharmaceutical wholesaler. Intellectual Property The company conducts research into new methods to synthesize treprostinil and has filed additional patent applications relating to production of treprostinil, several of which have already been granted in the United States. In addition to the treprostinil patents, the company has additional patents specific to its individual treprostinil-based products, including the following: Remodulin: The company has been granted three U.S. patents covering an improved diluent for Remodulin, which would expire in 2028 and 2029. Tyvaso: The company has been granted two U.S. patents, as well as patents in other countries for Tyvaso that cover methods of treating PAH by inhaled delivery. These patents would expire in the United States in 2018. Orenitram: The company’s patents for Orenitram cover methods of use for treating PAH, orally administered formulations, controlled moisture storage and production methods, as well as those covering controlled release formulations licensed to the company by Supernus Pharmaceuticals Inc. (Supernus). These patents would expire in the United States between 2024 and 2031 and in various countries throughout the world between 2024 and 2027. The company has additional pending U.S. and international patent applications relating to Remodulin, Tyvaso and Orenitram. Research and Development The company’s research and development expenses, as of December 31, 2013, totaled approximately $299.3 million. Suppliers Accredo Health Group, Inc. and CVS Caremark distributes and sells Remodulin and Tyvaso in the United States. Eli Lilly and Company manufactures and supplies Adcirca for the company. History United Therapeutics Corporation was founded in 1996. The company was incorporated in Delaware in 1996.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €124.22 EUR -2.19

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.102.00 CHF +1.20
Alexion Pharmaceuticals Inc $183.24 USD -4.81
Celanese Corp $53.76 USD -0.08
Nippon Shinyaku Co Ltd ¥3,905 JPY +100.00
Vertex Pharmaceuticals Inc $110.14 USD -4.00
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 40.1x
Price/Sales 5.5x
Price/Book 5.7x
Price/Cash Flow 34.9x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.